Table 2

Oncologic outcomes of patients with high-grade neuroendocrine cervical carcinoma

Author	Year	N	Type	Stage	DFS (months)	OS (months)	5-year DFS (%)	5-year OS (%)
Chan³⁸	2003	34	Multicenter	I-IIA IIB-IVB		31 10	32 0
Weed44	2003	15	Single institution	All stages			13
Viswanathan⁴⁵	2004	21	Single institution	IB1-IIIB		41		29
Chen⁵	2008	288	SEER	All stages				36
Lee⁵²	2008	68	Multicenter	IB1				55
				IB2-IIA All stages		54		32 47
Zivanovic⁷⁷	2009	17	Single institution	All stages IA1-IB2 IIB-IV		21 31 6	22
Cohen¹⁰	2010	188	SEER + 52 patients from four hospitals	I-IIA IIB-IVA IVB			37 10 0
Wang⁴²	2012	179	Multicenter	All stages IIB-IVB	16	25 (CSS)	43*; 63†
Yin⁶⁴	2015	23	Single institution	I-IIIB				40
Stecklein⁴¹	2016	32	Single institution	All stages			20	27
Lee69	2016	61	Multicenter	All stages		64		36
Xie65	2017	48	Single institution	All stages		30		31
Ishikawa¹¹¹¹	2018	93	Multicenter	IA-IIB	47	111	49	55
Tempfer¹³	2018	3538	Meta-analysis	All stages	16	40		34

*Primary treatment containing etoposide and platinum for at least five cycles.
†Concurrent chemoradiation with etoposide and platinum for at least five cycles.
CSS, Cancer Surveillance System; DFS, disease-free survival; OS, overall survial; SEER, Surveillance, Epidemiology, and End Results Program.